

symptoms, those with the strongest outstrength were worthlessness, hopelessness, low happiness, dropping activities/interests, and low satisfaction with life (all  $p < .01$ ).

**Conclusions:** We found a strong temporal link between depressive symptoms and subsequent cognitive decline in a population of the oldest old. This highlights the importance of a holistic approach that considers both mental and cognitive well-being in the aging population. As depressive symptoms were an early indicator of cognitive decline, it is of importance that healthcare professionals recognize and address depressive symptoms early to allow for appropriate interventions and support, to potentially mitigate the impact on cognitive decline.

**Disclosure of Interest:** None Declared

## Oncology and Psychiatry

### O0062

#### Prevalence of depressive disorders in breast cancer patients

R. A. Starostin<sup>1\*</sup>, S. V. Kuzmina<sup>2</sup> and I. G. Gataullin<sup>3</sup>

<sup>1</sup>LLC «Druzhkov Clinic»; <sup>2</sup>FBElOHE KSMU MOH Russia and <sup>3</sup>KSMA - Branch Campus of the FSBEIPE RMACPE MOH Russia, Kazan, Russian Federation

\*Corresponding author.

doi: 10.1192/j.eurpsy.2024.190

**Introduction:** Breast cancer is the most common type of cancer and the leading cause of death from malignant neoplasms in women in Russia and in most countries in the world (Lima *et al.* *EClinicalMedicine* 2021; 38 100985). According to an analysis of the incidence and mortality from 36 cancers in 185 countries (Sung *et al.* *CA Cancer J Clin* 2021. 3 209-249) in 2020, 2261419 new cases of breast cancer were identified in the world in both sexes, which is accounted for 11.7% of the total cancer incidence. Mortality from breast cancer in 2020 amounted to 684996 cases. Patients with comorbid depression and anxiety disorders experience more severe symptoms, have longer recovery time, use more healthcare resources and have poorer outcome compare to those with cancer alone (Katon *et al.* *Gen Hosp Psychiatry* 2007; 2 147-155).

**Objectives:** Analytical review of data on the impact of depressive spectrum disorders as comorbid conditions on the survival of breast cancer patients and their quality of life.

**Methods:** The following databases were searched for publications: PubMed, Embase, CINAHL, PsycINFO, Scopus, Science Citation Index/Social Sciences Citation Index, Cochrane Evidence Based Medicine database. The searches were limited to English language and studies with more than 100 subjects with diagnosed breast cancer where this information was mentioned. The analyzed period is between 1977 and 2018.

**Results:** The reported prevalence of depression in breast cancer patients, according to researches, varies 4,5 to 38%. In patients with I-III stage breast cancer depression increased hazards of all-cause mortality by 50% compared to non-depressed patients. Stage-specific analyses demonstrated a 2–2.5 fold increase in breast cancer-specific and all-cause mortality in patients with stage I

and II disease (Vodermaier *et al.* *Breast Cancer Res Treat* 2014; 2 373-384.). Women with non-metastatic breast cancer who report mild to moderate depressive symptoms in the weeks after surgery have approximately 2.5 times greater risk of death 8–15 years later than women who report little or no depressive symptoms post-surgery (Antoni *et al.* *Gen Hosp Psychiatry* 2017; 44 16-21). Depression in advanced cancer not only reduces quality of life but is also an independent predictor of poorer survival (Lloyd-Williams *et al.* *J Affect Disord* 2009; 113 127-132.).

**Conclusions:** Depression and anxiety both have adverse effects on recurrence and all-cause mortality in patients with breast cancer. Untreated depression leads to significant increase in incidence and mortality. Depression can debut at any stage of cancer, including the stage of diagnosis. It proves the necessity for affective disorders screening in patients with cancer on the stage of diagnosis. Patients with diagnosed affective disorders should be observed not only by oncologist, but also by a psychotherapist in order to receive the necessary treatment to improve the quality of life and reduce the risk of mortality.

**Disclosure of Interest:** None Declared

## Pain

### O0063

#### Combined effects of psychological and life style factors on pain intensity and/or disability in patients with chronic low back pain: A cross-sectional study

E. Tsatsaraki<sup>1</sup>, I. Bouloukaki<sup>2</sup>, G. Kontakis<sup>3</sup>, A. Vakis<sup>4</sup>, A. Miliaras<sup>5</sup> and M. Basta<sup>5\*</sup>

<sup>1</sup>Surgery; <sup>2</sup>Social and Family Medicine; <sup>3</sup>Orthopaedics and Traumatology; <sup>4</sup>Neurosurgery and <sup>5</sup>Psychiatry, University of Crete, School of Medicine, Heraklion, Greece

\*Corresponding author.

doi: 10.1192/j.eurpsy.2024.191

**Introduction:** Chronic Lower Back Pain (CLBP) is a frequently encountered health issue in primary care settings, leading to global disability and imposing a considerable economic burden.

**Objectives:** This study aimed to: (1) compare socio-demographic, health, lifestyle (sleep, physical activity) and psychological factors (depression, anxiety) between people with and without CLBP; and (2) quantify the correlations between these psychological and lifestyle factors, and clinical outcomes (intensity of CLBP and CLBP-related disability) in people with CLBP after considering other confounders.

**Methods:** A cross-sectional study was undertaken at the neurosurgery and orthopedic outpatient department of Heraklion University Hospital between 2019-2021. Two hundred fifty three volunteers with CLBP and 116 without CLBP provided socio-demographic information, daily habits, medical history, subjective sleep/ sleep complaints, low back pain intensity and disability using a 10-point numeric Visual Analogue Scale pain rating scale and Quebec Back Pain Disability Scale, as well as questions assessing impact of pain on mobility, self-care, routine activities and psychological status, respectively. Participants also completed the Zung Self-Rating Scale (SDS) for self-assessment of depression and